[HTML][HTML] Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation
Q Wang, Y Liu, Z Li, Y Tang, W Long, H Xin… - Frontiers in …, 2023 - frontiersin.org
Background Gastric cancer (GC) represents a malignancy with a multi-factorial combination
of genetic, environmental, and microbial factors. Targeting lysosomes presents significant …
of genetic, environmental, and microbial factors. Targeting lysosomes presents significant …
Major histocompatibility complex class II in the tumor microenvironment: functions of nonprofessional antigen-presenting cells
AM Macy, LM Herrmann, AC Adams… - Current Opinion in …, 2023 - Elsevier
Highlights•Tumor cell-specific MHCII (tsMHCII) decreases in vivo tumor growth via T
cells.•TsMHCII is associated with improved patient survival and response to ICI.•ApCAFs …
cells.•TsMHCII is associated with improved patient survival and response to ICI.•ApCAFs …
Interferon‐γ inducible protein 30 promotes the epithelial–mesenchymal transition‐like phenotype and chemoresistance by activating EGFR/AKT/GSK3β/β‐catenin …
Y Chen, H Xu, P Yu, Q Wang, S Li, F Ji… - CNS Neuroscience & …, 2023 - Wiley Online Library
Aims Previous studies have indicated that IFI30 plays a protective role in human cancers.
However, its potential roles in regulating glioma development are not fully understood …
However, its potential roles in regulating glioma development are not fully understood …
Interferon Gamma Inducible Protein 30: from biological functions to potential therapeutic target in cancers
S Zhang, L Ren, W Li, Y Zhang, Y Yang, H Yang, F Xu… - Cellular Oncology, 2024 - Springer
Abstract Interferon Gamma Inducible Protein 30 (IFI30), also known as Gamma-Interferon-
Inducible Lysosomal Thiol Reductase (GILT), is predominantly found in lysosomes and the …
Inducible Lysosomal Thiol Reductase (GILT), is predominantly found in lysosomes and the …
[HTML][HTML] Post-Transcriptional Induction of the Antiviral Host Factor GILT/IFI30 by Interferon Gamma
T Nakamura, M Izumida, MB Hans, S Suzuki… - International Journal of …, 2024 - mdpi.com
Gamma-interferon-inducible lysosomal thiol reductase (GILT) plays pivotal roles in both
adaptive and innate immunities. GILT exhibits constitutive expression within antigen …
adaptive and innate immunities. GILT exhibits constitutive expression within antigen …
[HTML][HTML] Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors
J Zhang, G Yin, C Ye, M Feng, C Ji… - Chinese Journal of …, 2024 - ncbi.nlm.nih.gov
Objective Primary resistance to trastuzumab frequently occurs in human epidermal growth
factor receptor 2 (HER2)-positive (+) breast cancer patients and remains a clinical …
factor receptor 2 (HER2)-positive (+) breast cancer patients and remains a clinical …
IFI30 as a key regulator of PDL1 immunotherapy prognosis in breast cancer
L Li, Y Fei, T Dong, Y Song, X Chen, H Zhang… - International …, 2024 - Elsevier
Background IFI30 is a lysosomal thiol reductase involved in antigen presentation and
immune regulation in various cancers, including breast cancer. Despite its known …
immune regulation in various cancers, including breast cancer. Despite its known …
[HTML][HTML] High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition
Simple Summary Skin cancer is the most common type of cancer, with melanoma being
among the deadliest of skin cancers due to its propensity to metastasize. Immune checkpoint …
among the deadliest of skin cancers due to its propensity to metastasize. Immune checkpoint …
Potential biomarkers and drug targets in glycoproteome of MCF-7 breast cancer cells based on proteomics and bioinformatics strategies Running title: Protein drug …
FS Sadjjadi, Z Molavi, D Rahmani, H Zali - 2024 - researchsquare.com
Identifying differentially expressed glycoproteins (DEGs) during cancer progression is an
excellent approach to discovering novel biomarkers. The current study investigated detected …
excellent approach to discovering novel biomarkers. The current study investigated detected …
IFI30 Modulates Immune Microenvironment And Improves Prognosis In Glioblastoma
J Huang, G You, J Song, L Xue, C Lin - 2022 - researchsquare.com
Background Immunotherapy has brought new hope as a potentially effective treatment for
Glioblastoma (GBM). It is currently considered that an effective T cell immune strategy …
Glioblastoma (GBM). It is currently considered that an effective T cell immune strategy …